Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of HRS-7058 versus investigator's choice KRAS G12C inhibitor in previously treated advanced or metastatic KRAS G12C-mutant non-small cell lung cancer
CTR20261946Phase 3Active
- Sponsor
- Shandong Sende
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-7058 in non-small cell lung cancer (NSCLC), sponsored by Shandong Sende. Started May 2026; status: active.
02
Drugs
HRS-7058
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20261946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261946.